key: cord-1027759-mxoisbim authors: Monnier, Alexandra; Falcoz, Pierre-Emmanuel; Helms, Julie; Meziani, Ferhat title: Reply to Wengenmayer et al.: Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort! date: 2020-11-15 journal: Am J Respir Crit Care Med DOI: 10.1164/rccm.202007-2670le sha: e4e5afd9a43440c7e513c9c54afb73555bd05211 doc_id: 1027759 cord_uid: mxoisbim nan Reply to Wengenmayer et al. We read with interest the correspondence from Wengenmayer and colleagues. The authors suggested that we should have adjusted our ventilation strategy under extracorporeal membrane oxygenation (ECMO) to be more protective. As recommended in the Extracorporeal Life Support Organization (ELSO) guidelines (1), we maintained a high positive endexpiratory pressure (PEEP) and reduced VT to maintain a plateau pressure (PP) under 25 cm H 2 O, but we did not drastically reduce the respiratory rate and the driving pressure (DP). The measure of these two parameters are indeed associated with mortality at Day 1 of acute respiratory distress syndrome (ARDS) (2) but not the DP in patients with obesity (most of our patients) (3). Thus, reducing DP by decreasing VT in patients with obesity could probably not be the main goal when PP remains acceptable. Indeed, the LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study (2) did not show any superiority of the DP to predict mortality. Furthermore, even if the DP value at day 1 was associated with mortality, to date, optimizing this parameter during the following days is not correlated with survival. Knowing the specificity of coronavirus disease (COVID-19)-related ARDS (4) and the high rate of patients with obesity treated in our small cohort (58.8%), one could advance that our strategy might be more protective by preventing overdistension. Our cannulation strategy is much more a matter of debate: the double-lumen cannulas are indeed not recommended in first intension by ELSO (1) because their positioning can be longer and require the use of an ultrasound system. Regarding oxygenation and decarboxylation, this type of cannula is as efficient as conventional cannulation (5) . Our team is experienced in this type of cannulation, limiting the adverse events during cannulation. In view of the morphotype of our patients, a single jugular cannulation facilitated their halfseated position and nursing. Moreover, these cannulas have the advantage of encouraging patient mobilization (5) and potentially limiting the consumption of sedatives, which is not insignificant in the context of a period with work overload. Because this type of cannula is associated with more bleeding (6), we wondered if the high rate of bleeding in our series is facilitated by the cannula, anticoagulation, or the transfusion strategy. Our transfusion target is consistent with ELSO guidelines (1). Concerning the anticoagulation, neither of the two patients with serious hemorrhagic events were overanticoagulated, and the five other patients were transfused on minor bleedings or hemolysis without a negative impact on patient prognosis. On the other hand, we reported two oxygenator thrombosis and three thromboembolic events. Considering the high incidence of thrombotic events in patients with COVID-19 and the ELSO guidelines (1), our anticoagulation target seems to be reasonable. In our series, two patients died of refractory ARDS with pulmonary fibrosis making the respiratory weaning impossible after decannulation. Two patients developed refractory septic shock with a predominance of vasoplegia, making conversion to venoaterial ECMO (VA-ECMO) ineffective. One patient died during cannulation of cardiac tamponade, and one was on VA-ECMO. Thus, optimizing the support during the time either by converting to VA-ECMO or adding a second cannula would not have modified the mortality of our case series. It is important to note that the context of pandemic-induced work overload and the patients' management by interim intensivists who were not used to taking care of patients with ARDS with ECMO may explain some intensive care management difficulties and suboptimal ventilator settings. In conclusion, in the context of the pandemic, we have chosen a mastered management of our patients. However, ECMO implantation in refractory ARDS related to COVID-19 allowed more protective ventilation parameters, improving patient status. Our results highlighted a preference for an adaptation of ventilator parameters on the PP and moderate PEEP in this specific series characterized by more obese patients and 65% survival in the ICU. n To the Editor: We have read "Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study" by Ziehr and colleagues with great interest (1) . In this letter, the authors described characteristics and outcomes in 66 patients with coronavirus disease (COVID-19) managed with mechanical ventilation. It is a great pleasure to see that 62.1% of these patients were successfully extubated after 2-3 weeks of mechanical ventilation. However, a few questions arose after reading the paper. First, did all these patients definitely require intubation? Unfortunately, the authors didn't specify in their letter the indications they had used for intubation, as the higher proportion of successfully weaned patients might be explained by lower severity of COVID-19 pneumonia. As we can see from given data, the respiratory parameters at the ICU admission and during the first 5 days were not so critical. Second, why did 95% of patients receive vasopressors? A possible explanation can be seen in Figure 1 by Ziehr and colleagues. A high proportion of patients had PEEP levels exceeding 14 (14-20) cm H 2 O despite low recruitability demonstrated in COVID-19-associated acute respiratory distress syndrome (ARDS) (4) : 15 patients at Day 1 (22.7%), 20 patients at Day 2 (30%), and 21 patients at Day 5 (36.8%). This can lead to lung overdistension and acute cor pulmonale. On the contrary, the reduced PEEP levels in patients with COVID-19 resulted in an increase in lung compliance and a decrease in dead space ventilation in a small observational study (5) . Deep sedation can be another possible explanation of the high usage of vasopressors (data not presented). Third, why did the authors so often use neuromuscular blockade (in 42% of patients)? The benefit of neuromuscular blockers was shown in the ACURASYS trial, in which they were used in patients with Pa O 2 /FI O 2 less than 150 mm Hg in the first 48 hours of mechanical ventilation (6). If we look at Figure 1 by Ziehr and colleagues, we can see that only six patients (9%) had Pa O 2 /FI O 2 less than 150 mm Hg on Day 2. The neuromuscular blockade can lessen ventilator-induced lung injury by decreasing transpulmonary pressure swings in dependent lung regions in severe ARDS, but it is not the case for mild or moderate ARDS. Finally, we have a question about the prone position during mechanical ventilation. The authors declared that median PEEP was 13 (interquartile range, 12-15) cm H 2 O while supine and 14 (interquartile range, 12-15) cm H 2 O while prone, so the PEEP levels in prone position did not decrease and even increased. This seems useless because a prone position that decreases the lung superimposed pressure must lead to a decrease in the PEEP levels. ELSO Guideline Working Group. Extracorporeal Life Support Organization COVID-19 interim guidelines Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study Impact of the driving pressure on mortality in obese and non-obese ARDS patients: a retrospective study of 362 cases COVID-19 pneumonia: different respiratory treatments for different phenotypes? Comparison of the avalon dual-lumen cannula with conventional cannulation technique for venovenous extracorporeal membrane oxygenation Extracorporeal membrane oxygenation for critically ill patients with COVID-19-related acute respiratory distress syndrome: worth the effort?